Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Xeris Pharmaceuticals Inc 1375 West Fulton Street Suite 1300 Chicago IL 60607 USA

www.xerispharma.com P: 844-445-5704

Description:

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.

Key Statistics

Overview:

Market Capitalization, $K 247,197
Enterprise Value, $K 370,677
Shares Outstanding, K 140,453
Annual Sales, $ 163,910 K
Annual Net Income, $ -62,260 K
Last Quarter Sales, $ 44,390 K
Last Quarter Net Income, $ -13,390 K
EBIT, $ -33,170 K
EBITDA, $ -17,800 K
60-Month Beta 2.33
% of Insider Shareholders 4.36%
% of Institutional Shareholders 42.75%
Float, K 134,329
% Float 95.64%
Short Volume Ratio 0.49

Growth:

1-Year Return -22.40%
3-Year Return -54.05%
5-Year Return -83.44%
5-Year Revenue Growth 6,536.03%
5-Year Earnings Growth 90.98%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.10 on 03/06/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -0.45
EPS Growth vs. Prev Qtr -11.11%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

XERS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -610.76%
Return-on-Assets % -19.15%
Profit Margin % -37.98%
Debt/Equity -28.16
Price/Sales 1.53
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.05
Interest Coverage -1.39
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar